– Two preclinical posters highlighting the JTX-1484 program and LILRB household at SITC 2022 –
– Two medical posters highlighting information from the SELECT and INNATE trials at ESMO-IO –
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage firm centered on the discovery and improvement of novel most cancers immunotherapies and predictive biomarkers, at present introduced poster displays to be made at upcoming medical conferences. Two preclinical poster displays can be made at the SITC 2022 Annual Meeting being held in Boston, November 8-12. These will embrace preclinical information on the JTX-1484 program, which targets LILRB4, and a characterization of the expression and performance of LILRB receptors on human immune cells in tumor and blood samples throughout totally different most cancers varieties. Two medical poster displays can be made at the ESMO-IO 2022 Annual Congress being held in Geneva, December 7-9. The submitted summary for the JTX-8064 INNATE trial incorporates Phase 1 information, together with security, PK, and tumor response information. Jounce continues to anticipate to report preliminary medical information on at least 80 Phase 2 sufferers from the INNATE trial by finish of yr 2022. The submitted summary for the vopratelimab/pimivalimab SELECT trial consists of all information beforehand introduced on medical endpoints. Additional sturdiness information for sufferers who stay on examine can even be reported.
SITC Poster Details:
Poster Title: Preclinical analysis of JTX-1484, an anti-LILRB4 antagonist antibody, for re-programming of immunosuppressive myeloid cells
Presenter: Andre Cunha, Ph.D.
Abstract Number: 483
Location: Poster Hall positioned in Hall C
Date and Time: Thursday, November 10, 2022: 11:40 a.m.-1:10 p.m., 7:30 p.m.-9:00 p.m. ET
Poster Title: Overlapping and Distinct Patterns of LILRB Receptors Support Complementary Targeting Approach in Cancer
Presenter: Yasmin Hashambhoy-Ramsay, Ph.D.
Abstract Number: 945
Location: Poster Hall positioned in Hall C
Date and Time: Thursday, November 10, 2022: 11:40 a.m.-1:10 p.m., 7:30 p.m.-9:00 p.m. ET
The Poster Hall can be open from 9 a.m. to 9 p.m. on Thursday, November 10, 2022, and Friday, November 11, 2022.
ESMO-IO Poster Details:
Poster Title: Phase 1 Study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and mixture with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in sufferers (pts) with superior stable tumors.
Presenter: Okay. Papadopoulos (San Antonio, TX, United States of America)
Session Title and Location: Poster Display, Foyer ABC
Presentation Number: 172P
Date and Time: Thursday, December 8, 2022: 12:30 p.m.-1:15 p.m. CET
Poster Title: SELECT: A section 2 randomized trial evaluating 2 doses of vopratelimab (V) + pimivalimab (P) vs P in TISvopra chosen sufferers (pts)
Presenter: M. Gumus (Istanbul, Turkey)
Session Title and Location: Poster Display, Foyer ABC
Presentation Number: 181P
Date and Time: Thursday, December 8, 2022: 12:30 p.m.-1:15 p.m. CET
All posters can be accessible on the “Our Pipeline” part of the Jounce Therapeutics web site after presentation at www.jouncetx.com.
About Jounce Therapeutics:
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy firm devoted to remodeling the therapy of most cancers by creating therapies that allow the immune system to assault tumors and should present long-lasting advantages to sufferers by means of a biomarker-driven strategy. Jounce at present has a number of improvement stage applications ongoing whereas concurrently advancing extra early-stage belongings from its strong discovery engine primarily based on its Translational Science Platform. Jounce’s highest precedence program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist proven to reprogram immune-suppressive tumor related macrophages to an anti-tumor state in preclinical research. JTX-8064 is at present being investigated alone and together with pimivalimab (previously JTX-4014), Jounce’s inner PD-1 inhibitor, in a single monotherapy and 7 indication-specific mixture remedy cohorts in the Phase 1/2 INNATE trial and is at present enrolling sufferers with superior stable tumors in the Phase 2 portion of the examine. Jounce’s most superior product candidate, vopratelimab, is a monoclonal antibody that binds to and prompts ICOS, and is at present being studied in the SELECT Phase 2 trial. Pimivalimab is a PD-1 inhibitor meant for mixture use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce completely licensed worldwide rights to GS-1811 (previously JTX-1811), a monoclonal antibody focusing on CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For extra data, please go to www.jouncetx.com.
Cautionary Note Regarding Forward-Looking Statements:
Various statements on this launch regarding Jounce’s future expectations, plans and prospects, together with with out limitation, Jounce’s expectations concerning the timing, initiation or growth, progress, outcomes of and launch of information from medical trials of Jounce’s product candidates, together with JTX-8064, vopratelimab and pimivalimab, might represent forward-looking statements for the functions of the protected harbor provisions underneath The Private Securities Litigation Reform Act of 1995 and different federal securities legal guidelines and are topic to substantial dangers, uncertainties and assumptions. You shouldn’t place reliance on these forward-looking statements, which regularly embrace phrases corresponding to, “expect” or related phrases, variations of such phrases or the destructive of these phrases. Although Jounce believes that the expectations mirrored in the forward-looking statements are affordable, Jounce can not assure such outcomes. Actual outcomes might differ materially from these indicated by these forward-looking statements on account of varied vital elements, together with, with out limitation, Jounce’s skill to efficiently handle its medical trials; administration of Jounce’s provide chain for the supply of drug product and supplies to be used in medical trials and analysis and improvement actions; actions of regulatory companies, which can have an effect on the initiation, timing and progress of medical trials of Jounce’s product candidates; dangers that the COVID-19 pandemic might disrupt Jounce’s business and/or the international healthcare system extra severely than anticipated, which can have the impact of delaying enrollment and completion of Jounce’s ongoing medical trials, or delaying timelines or information disclosures and regulatory submissions for its product candidates; and people dangers extra totally mentioned in the part entitled “Risk Factors” in Jounce’s most up-to-date Annual Report on Form 10-Okay filed with the Securities and Exchange Commission in addition to discussions of potential dangers, uncertainties, and different vital elements in Jounce’s subsequent filings with the Securities and Exchange Commission. All such statements communicate solely as of the date made, and Jounce undertakes no obligation to replace or revise publicly any forward-looking statements, whether or not on account of new data, future occasions or in any other case.
Investor and Media Contact:
Eric Laub
Jounce Therapeutics, Inc.
+1-857-259-3853
[email protected]
